Kira Pharmaceuticals to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Oct. 13, 2022 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therap...
Stay updated with breaking news from Frederick Beddingfield. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CAMBRIDGE, Mass., Oct. 13, 2022 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therap...
Kira Pharmaceuticals to Present New Preclinical Data on Lead Asset KP104 at the 2022 European Meeting on Complement in Human Disease Conference - read this article along with other careers information, tips and advice on BioSpace
/PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, will...
The FDA has granted Orphan Drug designation to KP104 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
CAMBRIDGE, Mass. and SUZHOU, China, Aug. 2, 2022 /PRNewswire/ -- Kira Pharmaceuticals, a global clinical-stage biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, today announced the appointment of Angela (Hui) Yan as President of China and Asia Development and Operations. In this role, Ms. Yan will lead Kira's China division, overseeing clinical development execution and strategy as well as operational excellence for China and Asia. "We are excited to welcome a leader of Angela's caliber to oversee our China and Asia business,...